Next Article in Journal
Aqueous Prostaglandin Eye Drop Formulations
Next Article in Special Issue
Analgesic and Anti-Inflammatory Properties of Ethanolic Extract of Piper vicosanum Leaves
Previous Article in Journal
Development of Heterocyclic PPAR Ligands for Potential Therapeutic Applications
Previous Article in Special Issue
Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 14
Issue 10
10.3390/pharmaceutics14102141
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Comparative Evaluation of the Antiglycation and Anti-α-Glucosidase Activities of Baicalein, Baicalin (Baicalein 7-O-Glucuronide) and the Antidiabetic Drug Metformin

by
Guglielmina Froldi
*,
Francine Medjiofack Djeujo
,
Nadia Bulf
,
Emma Caparelli
and
Eugenio Ragazzi
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy
*
Author to whom correspondence should be addressed.
Pharmaceutics 2022, 14(10), 2141; https://doi.org/10.3390/pharmaceutics14102141
Submission received: 14 July 2022 / Revised: 3 October 2022 / Accepted: 4 October 2022 / Published: 9 October 2022
(This article belongs to the Special Issue Recent Advances in Natural Product Drugs)
Browse Figures
Review Reports Versions Notes

Abstract

:
The discovery of new oral antidiabetic drugs remains a priority in medicine. This research aimed to evaluate the activity of the flavonoid baicalein and its natural glucuronide baicalin, compared to the antidiabetic drug metformin, as potential antiglycation, anti–radical, and anti-α–glucosidase agents, in order to assess their potential role in counteracting hyperglycemia-induced tissue damage. The study considered: (i) the BSA assay, to detect the formation of advanced glycation end products (AGEs), (ii) the GK peptide–ribose assay, which evaluates the cross–linking between the peptide and ribose, and (iii) the carbonyl content assay to detect the total carbonyl content, as a biomarker of tissue damage. In addition, to obtain a reliable picture of the antiglycation capacity of the investigated compounds, DPPH scavenging and oxygen radical absorbance capacity (ORAC) assays were performed. Furthermore, the anti–α–glucosidase activity of baicalein and baicalin was detected. Furthermore, to estimate cell permeability, preliminarily, the cytotoxicity of baicalein and baicalin was evaluated in HT–29 human colon adenocarcinoma cells using the MTT assay. Successively, the ability of the compounds to pass through the cytoplasmic membranes of HT–29 cells was detected as a permeability screen to predict in vivo absorption, showing that baicalein passes into cells even if it is quickly modified in various metabolites, being its main derivative baicalin. Otherwise, baicalin per se did not pass through cell membranes. Data show that baicalein is the most active compound in reducing glycation, α-glucosidase activity, and free radicals, while baicalin exhibited similar activities, but did not inhibit the enzyme α–glucosidase.

1. Introduction

Diabetes mellitus (DM) is the fourth leading cause of death in developed countries and is an epidemic in many developing countries. Numerous factors are involved in the aetiology of type 2 diabetes mellitus (T2DM), such as genetic predisposition, lifestyle, and dyslipidemia [1,2]. In poorly controlled DM, chronic hyperglycemia accelerates the formation of advanced glycation end products (AGEs) and the overproduction of reactive oxygen species (ROS) [3,4,5,6], increasing oxidative stress and glycation [7]. Furthermore, AGEs are ingested through food and then absorbed into the organism [8]. Several investigations have shown that AGEs and ROS are involved in a wide spectrum of pathologies, including cardiovascular failure, rheumatoid arthritis, Alzheimer’s disease, and kidney disease [9,10,11]. Therefore, inhibition of glycation reactions and free radicals may be an effective approach to counteract diabetes-associated diseases [12].
α–Glucosidase plays a key role in the regulation of blood sugar, and its inhibition reduces glucose absorption from food carbohydrates, reducing the postprandial glycemic peak [13]. Several authors have reported that acarbose, a well–known drug inhibitor of α–glucosidase, improves glycaemia and increases the level of GLP–1 (glucagon–like peptide–1) [13,14]. However, acarbose treatment causes various gastrointestinal disturbances that may not be produced by plant–derived inhibitors [15,16]. Furthermore, the discovery of new antihyperglycemic agents with multiple targets capable of reducing glucose–induced damage, decreasing glycation, ROS, and α–glucosidase activity could be relevant for patients with DM.
Baicalein (5,6,7–trihydroxyflavone) and baicalin (7–β–d–glucuronic acid of 5,6–trihydroxyflavone, Figure 1) have been identified in various medicinal plants, mainly in the roots of Scutellaria baicalensis G. (also known as the Chinese skull cap or Huang-Qin) and in the bark of Oroxylum indicum [17]. Scutellaria baicalensis is one of the 50 fundamental herbs of traditional Chinese medicine, widely used as an anti–inflammatory, antiviral, antibacterial, and anticancer remedy [18,19]. Studies have reported that baicalein and baicalin have antioxidant, anti–inflammatory, immune–stimulating, and antiviral activities [19,20,21]. Baicalin could also act in various intestinal diseases, as it can suppress the PI3K/AKT signalling pathway to inhibit the production of Bcl–2 proteins [22,23]. Previous studies have shown that baicalein and baicalin exhibit potential antidiabetic activities [24]. In detail, baicalein reduces oxidative stress, expressions of iNOS and TGF-β1, and NF–κB activation [25,26]. Furthermore, in both insulin deficiency and insulin–resistant rat models, baicalein showed antiglycation and anti–inflammatory protective mechanisms by also reducing AGE formation [27]. However, other authors did not find inhibition of protein glycation induced by 50 mM d-fructose [28]. Thus, this point may require further investigation.
Metformin (1,1–dimethylbiguanide) is a first–line oral antihyperglycemic agent largely used in T2DM due to its ability to decrease liver glucose production and improve insulin activity in target tissues [29]. Therefore, metformin reduces glycaemia and increases glyoxalase I activity, thus decreasing the methylglyoxal formation, a well–known precursor of AGEs [30,31]. Furthermore, the authors reported the in vitro inhibitory effect of metformin on protein glycation through various mechanisms [32,33,34].
This research aimed to investigate by a series of in vitro assays the activity of baicalein and its natural glucuronide baicalin, compared to metformin, as potential antiglycation agents and antiradical agents, in order to assess any possible role in counteracting tissue damage linked to diabetes. Furthermore, the occurrence of specific hypoglycemic effects was evaluated by investigating their anti–α–glucosidase activity. To complete the evaluation of flavonoids also under a predictive pharmacokinetic aspect, the ability of baicalein and baicalin to pass through HT–29 cell membranes was studied to estimate their bioavailability.

2. Results and Discussion

2.1. Proteine Glycation Inhibition

Glycated albumin could be considered a diagnostic indicator for DM and has been proposed as a marker to evaluate atherosclerosis and coronary disease in diabetic patients [31]. To evaluate the capacity of the flavonoids baicalein and its natural 7–O–glucuronide baicalin, and the drug metformin to inhibit protein glycation and fluorescent AGE formation, three assays were used to evaluate different steps of glycation reactions (Supplementary Figure S1). First, the BSA assay was performed to evaluate the ability of the selected compounds to reduce the AGE formation by the reaction between albumin and glycation agents. Second, the GK peptide–ribose assay was performed to estimate the ability of the compounds to inhibit peptide cross–linking; and third, the carbonyl content assay was performed, which measures the binding of DNP to protein carbonyls to detect the total amount of carbonyl–derived compounds in BSA–ribose glycation.

2.1.1. BSA Assay

Glucose, glyoxal, and ribose were used as glycation inducers to detect the formation of AGEs in vitro. A nine-day course assay was performed showing that glucose, glyoxal, and ribose have different glycation capacities (Figure 2).
Ribose was a powerful glycation agent with maximal AGE formation after 5 days of incubation with BSA (Figure 2A). Glyoxal induced maximal glycation after seven days of incubation, while glucose was a very weak glycation inducer, with a slight increase in fluorescence after seven-nine days (Figure 2A). Therefore, the experimental protocols were set at five days for ribose and seven days for glyoxal and glucose; mean maximal glycation values are reported in Figure 2B. Under these different conditions, the ability of baicalein, baicalin, and metformin to reduce the formation of AGEs was studied (Figure 3).
In the glucose–BSA glycation test, both baicalein and baicalin significantly inhibited AGE formation from the concentration of 5 µM, while metformin did not show any significant inhibition (Figure 3A). Glyoxal-induced BSA glycation was inhibited by 10 µM baicalein and 5 µM baicalin (Figure 3B). Finally, with ribose, which causes the highest glycation, both baicalein and baicalin maintained their ability to reduce glycated albumin from the concentration of 5 µM, whereas metformin, as in the previous tests, did not achieve any protection (Figure 3C). Previous research suggested that metformin could be a moderate inhibitor of glycation, possibly due to its interaction with dicarbonyl compounds generated during the glycation process [34]. However, the concentration used in the reported in vitro study was elevated, as well as 1 mM, which is a very higher concentration, higher than the therapeutic level of the drug [33]. In fact, the therapeutic range is minor at 1.5 µM (max 5 µM), even if rarely, higher concentrations have been detected [35,36]. In our experimental condition, metformin (1–100 µM) did not show a significant effect even if a slight inhibition trend was observed (Figure 3).

2.1.2. GK Peptide–Ribose Assay

This investigation was performed to evaluate the ability of the compounds to reduce peptide cross–linking, a process that occurs in the last phase of glycation. In the beginning, GK glycation was detected each day for up to 4 days, showing that AGE formation reached its maximum after 2 days (Figure S2). Therefore, the assay was performed after 2 days of incubation. It should be noted that baicalein (1–100 µM) inhibited AGE formation in a concentration–dependent manner (Figure 4). The IC50 was 49.7 ± 0.5 µM (pD2 = 4.3). Interestingly, its glucuronide derivative baicalin, tested in the same baicalein concentration range, only slightly and not significantly reduced the cross–linking of the GK peptide (Figure 4). As expected, metformin was not active as a linking inhibitor, in agreement with the results obtained with the BSA assay (Figure 4).

2.1.3. Carbonyl–Protein Content Assay

The generation of ROS during glycation and glycoxidation is capable of oxidizing the side chains of amino acid residues in protein to form carbonyl–protein derivatives, which are well–known to mediate free radical–induced damage to various biological macromolecules [37]. Therefore, the carbonyl content is considered an indicator of glycation and is used as a parameter to evaluate protein oxidation [38]. In this experimental step, metformin was not investigated because its antiglycation activity was very low in previous tests. Both baicalein and baicalin exhibited a detectable ability to reduce carbonyl increase in the concentration range of 10–100 µM, and baicalin also inhibited carbonyl formation at the lowest concentration tested of 5 µM. However, the inhibitory effects of both compounds were not concentration dependent, resulting in approximately 15–25% (Figure 5). Recently, some authors suggested that a sage methanol extract (0.25–1.00 mg/mL) significantly decreased BSA carbonyl formation [39], while other authors reported that single compounds, such as rosmarinic acid and carnosic acid (6.25–400 µM), decreased carbonylation [38]. Previously, various flavonoids, including baicalein, have been reported to decrease protein carbonylation in goat eye lenses [40].

2.2. Free Radical Inhibition

Hyperglycemia and ROS increase the formation of AGEs through oxidative steps (glycoxidation) [41]. For the evaluation of the antioxidant activity of the compounds under examination, two assays were used: (i) the DPPH assay, for which the reduction of the reference radical occurs by the transfer of a single electron to the radical molecule (single electron transfer mechanism, SET) [42]; and (ii) the ORAC assay, for which the compounds examined oxidize by donation of a hydrogen atom to radical molecules (hydrogen atom transfer mechanism (HAT) [43].

2.2.1. DPPH• Assay

Figure 6A shows the antiradical activity of the two flavonoids and metformin tested in the range of 0.1 to 500 µM. Ascorbic acid and N–acetylcysteine (NAC) were used as positive controls. Both baicalein and baicalin showed an antioxidant capacity comparable to that of the standard ascorbic acid, showing excellent scavenger activity. These compounds reach their maximum effect at the highest concentrations (≥50 µM), while NAC showed a lower potency, and metformin did not show any scavenging effect. Based on antiradical profiles, it was possible to quantify antioxidant efficacy by calculating the EC50 values, a parameter that indicates the effective substrate concentration that causes 50% of the maximum antioxidant response [44]. Potency values expressed as pD2 (−log EC50) are 4.91 ± 0.01 for baicalein and 4.89 ± 0.03 for baicalin, comparable to those of ascorbic acid (4.77 ± 0.04), and higher than those of NAC (4.38 ± 0.02, p < 0.05).

2.2.2. ORAC Assay

Based on a different antiradical mechanism such as peroxyl radical scavenging capacity, the ORAC assay was performed [45]. Baicalein and baicalin antiradical activities were very similar and approximately ten times higher than metformin; the TEAC values were 5.41 ± 0.33, 5.90 ± 0.23, and 0.48 ± 0.10 µmol TE/µmol, respectively (Figure 6B). Ascorbic acid and NAC, standard antioxidants (0.65 ± 0.01 and 1.45 ± 0.01 µmol TE/µmol), showed lower activity than both flavonoids. The order of antioxidant activity was baicalin ≥ baicalein >> NAC > ascorbic acid ≥ metformin.
The results obtained with DPPH• and ORAC assays agree with those of Gao et al. who suggested that flavonoids with o–dihydroxyl structure in the A ring are effective radical scavengers [20]. These can reduce the formation of AGEs by scavenging free radicals produced in the early phase of the glycation process [46]. Thus, the quenching of ROS by antioxidants such as baicalein and baicalin can contribute to the reduction of AGE production.

2.3. Anti-α–glucosidase Activity

The inhibitory activity of baicalein and baicalin was studied using the α–glucosidase assay, with pNPG as substrate and acarbose as positive control [47,48]. The absorbance curves were detected during the 60 min reaction between enzyme (0.05 µM) and pNPG (2 mM) alone and in the presence of different concentrations of baicalein (1–100 µM), revealing a concentration-dependent inhibition of enzyme activity (Figure 7A). Interestingly, under the same conditions, baicalin did not induce any modification of the α–glucosidase activity (Figure S3), suggesting that only the flavonoid aglycone could interact with the enzyme catalytic task. This observation is consistent with a previous study showing for baicalin an IC50 greater than 400 µM against rat α–glucosidase in vitro [49]. Therefore, an in–depth study on the enzyme was performed only with baicalein, as a potential new α–glucosidase inhibitor. Four α–glucosidase concentrations (0.035, 0.05, 0.07 and 0.1 µM) were tested to study the type of inhibition induced by baicalein (Figure S4 and Figure 7B).
Always, baicalein exhibited concentration–dependent inhibition, even with lower potency at higher enzyme concentrations (Figure 7B,C). Thus, the baicalein IC50 values increased at higher enzyme concentrations (Table 1). Baicalein 50 µM inhibited 0.035 and 0.05 µM α–glucosidase activity of about 90% and 75%, respectively.
To study the type of interaction between α–glucosidase and baicalein, the plot of enzyme activity (v) versus α–glucosidase enzyme concentration was obtained (Figure 7C), suggesting a concentration–dependent reversible interaction since all straight lines obtained at different concentrations of baicalein pass through the origin of the axes, and their slope decreased with increasing concentrations of the inhibitor. Previous research showed similar behavior for other natural compounds, for example, luteolin, morin, magnolol, and α–mangostin [48,50,51,52]. Furthermore, the type of baicalein inhibition was also estimated with Michaelis–Menten and Lineweaver–Burk plots (Figure 8A,B) obtained using different substrate concentrations (0.5, 1.0, 1.5 and 2.0 mM pNPG), while maintaining constant enzyme concentration (0.05 µM). The Lineweaver–Burk plot shows the intersection of lines in the second quadrant, as a result of the change in both Vmax and Km at different concentrations of baicalein, suggesting a mixed–type (mixture of competitive and non–competitive) mechanism of enzyme inhibition. When applying a mixed–model inhibition, Vmax was 0.0926 ∆OD/min, Km was 0.24 mM, and the baicalein inhibition constant (Ki) was 25.89 µM. The baicalein Ki is very similar to those reported by other authors: 45 µM [53], 44 µM [54], and 14.6 µM [49].

2.4. Cellular Uptake

The cytotoxicity assay was performed to see whether flavonoids could modify cell proliferation in culture and to determine the baicalein concentrations that would be useful to perform the uptake assay. The human colorectal adenocarcinoma (HT–29) cell line is a suitable model for bioavailability measurements thanks to its similarities, both in phenotype and in enzyme expression, with mature intestinal cells such as enterocytes [55]. Baicalein was tested from 0.1 to 50 µM after 24 h of incubation, displaying a slight inhibition of HT–29 cell viability; pD2 = 4.44 ± 0.09, showing low cytotoxicity (Figure S5).

Cellular Uptake of Baicalein in HT–29 Cells

The HT–29 cell line was used to study the ability of baicalein and baicalin to pass through the cellular membrane and therefore permeate into cells, estimating their bioavailability. The amount of compounds at extracellular and intracellular levels was detected by high–performance liquid chromatography (HPLC), equipped with a UV diode array detector. Preliminarily, cellular uptake was estimated by adding baicalein in a concentration range from 1 to 50 µM to the cell medium. Unexpectedly, after 30 min–3 h of incubation, it was observed that baicalein was no longer measurable and only three metabolites were detectable. In detail, the major component detected was the glucuronide derivative baicalin (Figure 9: peak 1, baicalin), both at the extra– and intracellular levels. Figure 10A shows that intracellular uptake increased with increasing baicalein concentrations in cell medium (3 h of incubation). Based on these data, subsequent tests were performed using baicalein at 5 µM, a concentration with low inhibitory activity on cell viability (−25% of the control).
After incubation with 5 µM baicalein, the glucuronide baicalin was identified both at the intracellular level: 0.60 ± 0.20 nmol/mg protein and at the extracellular level: 0.91 ± 0.24 µM. The results showed that the flavonoid baicalein is capable of passing through the HT–29 cell membranes and can also undergo a biotransformation process that leads to various metabolites (Figure 9 and Figure 10). The main metabolite has been identified as baicalein–7–glucuronide, the conjugated form of baicalein (phase II metabolism) that corresponds to baicalin. Otherwise, 5 µM baicalin was only slightly taken up in the intracellular compartment (0.069 ± 0.001 nmol/mg protein, Figure 10B). Baicalin remained for the most part in the extracellular compartment (3.02 ± 0.29 µM), showing a low ability to cross cell membranes. These data agree with various types of research that have indicated the conspicuous intestinal and liver metabolism of baicalein into baicalin through UDP–glucuronosyltransferases and the low bioavailability of baicalin [56,57,58,59].

3. Materials and Methods

3.1. Reagents

Acarbose, 2,2′–azobis(2–amidinopropane)–dihydrochloride (AAPH), baicalein (5,6,7–trihydroxyflavone), baicalin (7–β–d–glucuronic acid of 5,6–trihydroxyflavone), bovine serum albumin (BSA), 3–[4,5–dimethylthiazol–2–yl]–2,5 diphenyl tetrazolium bromide (MTT), 1,1–diphenyl–2–picrylhydrazil (DPPH•), α–glucosidase (EC 3.2.1.20, Saccharomyces cerevisiae type I, 10 U/mg protein), 6–hydroxy–2,5,7,8–tetramethylchroman–2–carboxylic acid (trolox), metformin, p–nitrophenyl–α–d–glucopyranoside (pNPG) and, generally, all chemicals and solvents were purchased from Merck KGaA, Darmstadt, Germany. Otherwise, the N–acetyl–glycyl–lysine methyl ester (GK) peptide was obtained from Bachem (Bachem AG, Bubendorf, Switzerland). The purity of the reference standards was 97%, while other chemicals were of at least analytical grade.

3.2. Protein Glycation Inhibition

3.2.1. BSA Assay

Glycated BSA was obtained according to a previously reported method [48,60]. Briefly, AGEs were detected using BSA (50 mg/mL, pH 7.4), as protein substrate, and glucose (0.8 M), glyoxal (0.003 M) or ribose (0.1 M), as glycation agents. Each inhibitor was tested in the range of concentrations of 1–100 µM by adding to substrate solutions and incubation at 37 °C for a time of 5 (ribose) or 7 (glucose and glyoxal) days. The fluorescence intensity was measured at an excitation wavelength of 355 nm and an emission wavelength of 460 nm with a PerkinElmer Victor Nivo microplate reader (Waltham, MA, USA). Inhibition of AGE formation was calculated as the fluorescence difference between glycation under the control condition and in the presence of each inhibitor. Aminoguanidine (2.5 mM, AG) was used as a positive control [61].

3.2.2. GK Peptide–ribose Assay

The N–acetyl–glycyl–lysine methyl ester (GK) peptide–ribose assay was performed with some modifications to a published method [62]. Briefly, GK peptide (27 mg/mL), a synthetic model peptide, was incubated with 40 mg/mL (0.27 M) d–ribose in sodium phosphate buffer (pH 7.4) and test samples were added at final concentrations ranging from 1.0–100 μM. After 48 h of incubation, fluorescence was read at 355 and 460 nm for excitation and emission wavelengths, respectively, with a PerkinElmer Victor Nivo microplate reader (Waltham, MA, USA). The fluorescence measurement allows the calculation of GK peptide glycation inhibition as a percentage difference between the control condition and glycation in the presence of the inhibitor. Aminoguanidine (2.5 mM, AG) was used as a positive control.

3.2.3. Carbonyl Content Assay

The total protein–bound carbonyl content was determined by derivatization of the carbonyl group with 2,4–dinitrophenylhydrazine (DNPH), which leads to the formation of a stable dinitrophenylhydrazone product [63], which was monitored spectrophotometrically at 375 nm with a PerkinElmer Victor Nivo microplate reader (Waltham, MA, USA). Glycated BSA samples were mixed with DNPH solution (10 mM in 2.0 M HCl) for 1 h at 37 °C in the dark. The proteins were precipitated with 20% trichloroacetic acid. The mixture was centrifuged at 10,000× g rpm, 10 min at 4 °C, to obtain a pellet and the supernatant was removed. DNPH was removed by extracting the pellet twice using a solution of ethyl acetate/ethanol (1:1). Lastly, the pellet was dissolved in guanidine hydrochloride (6 M) before reading the absorbance at 375 nm. The concentration of DNPH derivatized proteins was determined by the molar extinction coefficient of 22,000 M−1 cm−1 [64]. The protein concentration was measured using a BCA assay [65], and the protein carbonyl concentration was expressed as nmol/mg of protein. Aminoguanidine (2.5 mM, AG) was used as a positive control.

3.3. Free Radical Inhibition

3.3.1. DPPH• Assay

The free radical scavenging activity of the samples was measured using the DPPH• method [66]. Sample solutions were prepared and added to 70 µM DPPH•; the mixtures were kept in the dark for 60 min and absorbance was read at 517 nm using a Beckman Coulter DU 8005 spectrophotometer (Fullerton, CA, USA). The radical scavenging capacity was expressed as a percentage effect.

3.3.2. ORAC Assay

The radical oxygen absorption capacity (ORAC) assay was performed as previously described [67]. Briefly, trolox was prepared in phosphate buffer over a concentration range of 6.25 to 50 µM. In 24–well plates, 1.5 mL of fluorescein (0.08 µM) was added, followed by 250 µL of trolox for the control, 250 µL of buffer for the blank, and 250 µL of each inhibitor (5.0 µM). After 10 min of incubation, at 37 °C, 250 µL of 0.15 M AAPH was added. Successively, the PerkinElmer Victor Nivo microplate reader (Waltham, MA, USA) was settled for a fluorescence kinetic reading at 37 °C for one hour, with excitation and emission wavelengths, respectively, of 485 and 530 nm. The results were expressed in TEAC (trolox equivalent antioxidant capacity, TE µmol/µmol compound).

3.4. α– Glucosidase Inhibition

The inhibitory activity of baicalein and baicalin was studied using the yeast α–glucosidase assay, using pNPG as a substrate. The enzyme acts by hydrolyzing pNPG into α–d–glucopyranoside and p–nitrophenol (yellow); the reaction was detected at different inhibitor concentrations by variation in chromatic intensity [47,48]. Acarbose (1.25 M) was used as a positive control. Each sample was incubated with several α–glucosidase concentrations (0.035, 0.05, 0.07 and 0.1 µM) in PBS solutions (pH 6.8) for 10 min, at 37 °C. The reaction started with the addition of pNPG. Absorbance values were detected at 405 nm for 60 min, using a PerkinElmer Victor Nivo microplate reader spectrophotometer (Waltham, MA, USA). The half–maximal inhibitory concentration (IC50) was estimated by the plot of relative enzyme activity versus inhibitor concentration. The type of enzyme inhibition exerted by baicalein was evaluated from kinetic studies using different substrate concentrations (0.5, 1.0, 1,5 and 2.0 mM pNPG) through the Michaelis–Menten and Lineweaver–Burk plots.

3.5. Cellular Uptake

3.5.1. MTT Assay

Cell viability was assessed with the MTT assay [46]. HT–29 cells were seeded in a 96–well plate at a density of 5000 cells in each well and allowed to grow overnight. The cells were treated with various concentrations of the substances. After 24 h of incubation, an aliquot of MTT solution was added to each well, to reach the final concentration of 500 μg/mL. Subsequently, after the MTT reduction by cellular enzymes, the medium was removed and the insoluble formazan salts were solubilized with 2–propanol. The absorbance of each purple formazan solution was measured using a PerkinElmer Victor Nivo microplate reader (Waltham, MA, USA), at a wavelength of 520 nm.

3.5.2. HT–29 Uptake Assay

To evaluate the cellular uptake of compounds, a previously described method was used [68]. Briefly, HT–29 cells were seeded in a 6–well plate at a density of 500,000 cells in each well in a complete medium and allowed to grow until confluence for 48 h, at 37 °C (Figure 11). The culture medium was then removed and the cells were treated with each compound (5 µM). After incubation, an aliquot of the extracellular solution was taken from each well and stored at −20 °C for further analysis. The medium was then removed, the cells were washed with PBS and prepared for the following steps: (i) protein quantification, cells were lysed with 200 μL of lysis buffer and the wells were washed with 200 μL of PBS; and (ii) evaluation of cell uptake, cells were gently scraped with PBS, centrifuged at 1250× g rpm for 5 min, and added with 500 μL of 80% v/v methanolic solution in water/0,1% v/v acetic acid to extract intracellular content. The samples were kept on ice for 15 min, then sonicated and centrifuged at 20,000× g rpm for 10 min. Precipitated proteins were excluded, while supernatant solutions were collected for chromatographic analysis. The lysates and intracellular solutions were stored at −20 °C for HPLC–DAD analysis (Figure 11). The peaks were identified by comparing the chromatogram relative to the intracellular and extracellular contents with the chromatogram of each analytical standard.

3.5.3. High-Performance Liquid Chromatography (HPLC–DAD) Analysis

Chromatographic analyses were performed with an HPLC instrument (Waters Corporation, Milford, DE, USA) equipped with a 1525 binary HPLC pump and a 2998 photodiode array detector. A Symmetry® RP C18 column, 4.6 × 75 mm, 3.5 μm column (Waters, Milford, USA) was used. As previously reported [69], a linear methanolic gradient was applied from 20 to 80% v/v in 12 min (A: water with 0.1% v/v acetic acid, and B: methanol with 0.1% v/v acetic acid), with a flow rate of 1 mL/min. Peaks were detected in the range of 210–400 nm. All samples were filtered with membrane filters (0.22 μm pore size, Millipore, Merck KGaA, Darmstadt, Germany) and then injected (10 μL). Standard stock solutions were prepared in methanol. The amount of each compound was calculated using a standard calibration curve. The protein content of the lysate was detected using the Lowry protein assay [70], to express the results as nmol/mg protein.

3.6. Statistical Analysis

Data are expressed as mean ± SEM of at least three independent experiments. The sigmoid curve fitting and statistical evaluations were performed using GraphPad Prism 9 (San Diego, CA, USA). Statistical comparisons among three or more groups were performed using one–way ANOVA, followed by Dunnett’s multiple comparison test or Tukey’s test. The level of significance was established at p < 0.05.

4. Conclusions

This research shows that both baicalein and baicalin have appreciable antiglycation and antiradical activities comparable to each other. On the contrary, the drug metformin shows only modest antiradical activity, without the capacity to decrease glycation reactions. Furthermore, baicalein, but not baicalin, inhibits α–glucosidase activity. Therefore, the natural compound baicalein exhibits antiglycation, antioxidant and anti–α–glucosidase activities, while baicalin does not cause any enzyme inhibition. Baicalein exhibits a mixed–type reversible inhibition on α–glucosidase, showing a Ki of 25.89 µM. Natural compounds baicalein and baicalin show favorable antidiabetic properties, supporting their intake through diets or even plant-based preparations.
In particular, the predicted favorable absorption profile of baicalein makes this natural flavonoid a promising candidate for further investigations about the possibility of developing a formulation of baicalein, finding the appropriate dose and pharmaceutical preparation, to be used in the prevention of hyperglycemia–related diseases.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics14102141/s1, Figure S1: Scheme of AGE formation and protein carbonylation; Figure S2: GK–peptide kinetic curve obtained by measuring the fluorescence intensity at 355 nm excitation and 460 nm emission wavelengths over several days of incubation with 0.1 M ribose; Figure S3: An example of kinetic curves of 0.05 µM α–glucosidase and 2 mM pNPG in the presence of increasing concentrations of baicalin; Figure S4: Enzyme kinetics observed with different concentrations of α–glucosidase and 2 mM pNPG (A). Graph “v versus (α–glucosidase)” (B); Figure S5: Effects of baicalein on the viability of human colon adenocarcinoma (HT–29) cells.

Author Contributions

Conceptualization, G.F.; investigation, N.B. and E.C.; resources, G.F. and E.R.; data curation, G.F. and F.M.D.; writing–original draft preparation, G.F.; writing–review and editing, G.F., F.M.D. and E.R.; funding acquisition, G.F. and E.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research did not receive external funding. The APC was funded by MUR (Ministero dell’Università e della Ricerca, Italy).

Institutional Review Board Statement

Not applicable.

Data Availability Statement

All results are contained in the article and Supplementary Materials.

Acknowledgments

The authors acknowledge Maddalena Donati, who during her Ph.D. course supervised the setup of cell uptake protocols and lab organization.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hu, F.B. Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care 2011, 34, 1249–1257. [Google Scholar] [CrossRef] [Green Version]
  2. Mohan, V.; Ruchi, V.; Gayathri, R.; Bai, M.R.; Sudha, V.; Anjana, R.M.; Pradeepa, R. Slowing the diabetes epidemic in the World Health Organization South-East Asia Region: The role of diet and physical activity. WHO South East Asia J. Public Health 2016, 5, 5–16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Vezza, T.; Díaz-pozo, P.; Canet, F.; De Marañón, A.M.; Abad-jiménez, Z.; García-gargallo, C.; Roldan, I.; Solá, E.; Bañuls, C.; López-domènech, S.; et al. The Role of Mitochondrial Dynamic Dysfunction in Age-Associated Type 2 Diabetes. World J. Mens Health 2022, 40, 399–411. [Google Scholar] [CrossRef] [PubMed]
  4. Pantalone, K.M.; Hobbs, T.M.; Wells, B.J.; Kong, S.X.; Kattan, M.W.; Bouchard, J.; Yu, C.; Sakurada, B.; Milinovich, A.; Weng, W.; et al. Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system. BMJ Open Diabetes Res. Care 2015, 3, e000093. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Goh, S.Y.; Cooper, M.E. The role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 2008, 93, 1143–1152. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Madonna, R.; Pieragostino, D.; Balistreri, C.R.; Rossi, C.; Geng, Y.-J.; Del Boccio, P.; De Caterina, R. Diabetic macroangiopathy: Pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage. Vasc. Pharmacol. 2018, 107, 27–34. [Google Scholar] [CrossRef] [PubMed]
  7. Bierhaus, A.; Hofmann, M.A.; Ziegler, R.; Nawroth, P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc. Res. 1998, 37, 586–600. [Google Scholar] [CrossRef] [Green Version]
  8. Uribarri, J.; Cai, W.; Sandu, O.; Peppa, M.; Goldberg, T.; Vlassara, H. Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Ann. N. Y. Acad. Sci. 2005, 1043, 461–466. [Google Scholar] [CrossRef] [PubMed]
  9. Hanssen, N.M.J.; Stehouwer, C.D.A.; Schalkwijk, C.G. Methylglyoxal stress, the glyoxalase system, and diabetic chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2019, 28, 26–33. [Google Scholar] [CrossRef] [PubMed]
  10. Tarannum, A.; Arif, Z.; Alam, K.; Ahmad, S.; Uddin, M. Nitroxidized-albumin advanced glycation end product and rheumatoid arthritis. Arch. Rheumatol. 2019, 34, 461–475. [Google Scholar] [CrossRef]
  11. Prasad, K. AGE–RAGE stress: A changing landscape in pathology and treatment of Alzheimer’s disease. Mol. Cell. Biochem. 2019, 459, 95–112. [Google Scholar] [CrossRef] [PubMed]
  12. Rhee, S.Y.; Kim, Y.S. The role of advanced glycation end products in diabetic vascular complications. Diabetes Metab. J. 2018, 42, 188–195. [Google Scholar] [CrossRef] [PubMed]
  13. Godbout, A.; Chiasson, J.L. Who should benefit from the use of alpha-glucosidase inhibitors? Curr. Diabetes Rep. 2007, 7, 333–339. [Google Scholar] [CrossRef]
  14. Takei, I.; Miyamoto, K.; Funae, O.; Ohashi, N.; Meguro, S.; Tokui, M.; Saruta, T. Secretion of GIP in responders to acarbose in obese Type 2(NIDDM) patients. J. Diabetes Complicat. 2001, 15, 245–249. [Google Scholar] [CrossRef]
  15. Gupta, P.; Bala, M.; Gupta, S.; Dua, A.; Dabur, R.; Injeti, E.; Mittal, A. Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs—A mechanistic revisit to understand their mode of action. Pharmacol. Res. 2016, 113, 636–674. [Google Scholar] [CrossRef] [PubMed]
  16. Shahwan, M.; Alhumaydhi, F.; Ashraf, G.M.; Hasan, P.M.Z.; Shamsi, A. Role of polyphenols in combating Type 2 Diabetes and insulin resistance. Int. J. Biol. Macromol. 2022, 206, 567–579. [Google Scholar] [CrossRef]
  17. Dinda, B.; Dinda, S.; DasSharma, S.; Banik, R.; Chakraborty, A.; Dinda, M. Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders. Eur. J. Med. Chem. 2017, 131, 68–80. [Google Scholar] [CrossRef]
  18. Gaire, B.P.R.; Moon, S.K.; Kim, H. Scutellaria baicalensis in stroke management: Nature’s blessing in traditional Eastern medicine. Chin. J. Integr. Med. 2014, 20, 712–720. [Google Scholar] [CrossRef]
  19. Shen, Y.C.; Chiou, W.F.; Chou, Y.C.; Chen, C.F. Mechanisms in mediating the anti-inflammatory effects of baicalin and baicalein in human leukocytes. Eur. J. Pharmacol. 2003, 465, 171–181. [Google Scholar] [CrossRef]
  20. Gao, Z.; Huang, K.; Yang, X.; Xu, H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim. Biophys. Acta Gen. Subj. 1999, 1472, 643–650. [Google Scholar] [CrossRef]
  21. Gong, W.Y.; Zhao, Z.X.; Liu, B.J.; Lu, L.W.; Dong, J.C. Exploring the chemopreventive properties and perspectives of baicalin and its aglycone baicalein in solid tumors. Eur. J. Med. Chem. 2017, 126, 844–852. [Google Scholar] [CrossRef]
  22. Wang, X.; Xie, L.; Long, J.; Liu, K.; Lu, J.; Liang, Y.; Cao, Y.; Dai, X.; Li, X. Therapeutic effect of baicalin on inflammatory bowel disease: A review. J. Ethnopharmacol. 2022, 283, 114749. [Google Scholar] [CrossRef]
  23. Zhu, L.; Shen, H.; Gu, P.; Liu, Y.; Zhang, L.; Cheng, J. Baicalin alleviates TNBS-induced colitis by inhibiting PI3K/AKT pathway activation. Exp. Ther. Med. 2020, 20, 581–590. [Google Scholar] [CrossRef]
  24. Rahimi, V.B.; Askari, V.R.; Hosseinzadeh, H. Promising influences of Scutellaria baicalensis and its two active constituents, baicalin, and baicalein, against metabolic syndrome: A review. Phytother. Res. 2021, 35, 3558–3574. [Google Scholar] [CrossRef] [PubMed]
  25. Zhang, B.; Sun, W.; Yu, N.; Sun, J.; Yu, X.; Li, X.; Xing, Y.; Yan, D.; Ding, Q.; Xiu, Z.; et al. Anti-diabetic effect of baicalein is associated with the modulation of gut microbiota in streptozotocin and high-fat-diet induced diabetic rats. J. Funct. Foods 2018, 46, 256–267. [Google Scholar] [CrossRef]
  26. Bitew, M.; Desalegn, T.; Demissie, T.B.; Belayneh, A.; Endale, M.; Eswaramoorthy, R. Pharmacokinetics and drug-likeness of antidiabetic flavonoids: Molecular docking and DFT study. PLoS ONE 2021, 16, e0260853. [Google Scholar] [CrossRef] [PubMed]
  27. Prasanna, G.; Jing, P. Polyphenols redirects the self-assembly of serum albumin into hybrid nanostructures. Int. J. Biol. Macromol. 2020, 164, 3932–3942. [Google Scholar] [CrossRef] [PubMed]
  28. Boušová, I.; Martin, J.; Jahodář, L.; Dušek, J.; Palička, V.; Dršata, J. Evaluation of in vitro effects of natural substances of plant origin using a model of protein glycoxidation. J. Pharm. Biomed. Anal. 2005, 37, 957–962. [Google Scholar] [CrossRef] [PubMed]
  29. Khan, R.M.M.; Chua, Z.J.Y.; Tan, J.C.; Yang, Y.; Liao, Z.; Zhao, Y. From pre-diabetes to diabetes: Diagnosis, treatments and translational research. Medicina 2019, 55, 546. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Zendjabil, M. Glycated albumin. Clin. Chim. Acta 2019, 502, 240–244. [Google Scholar] [CrossRef] [PubMed]
  31. Song, Q.; Liu, J.; Dong, L.; Wang, X.; Zhang, X. Novel advances in inhibiting advanced glycation end product formation using natural compounds. Biomed. Pharmacother. 2021, 140, 111750. [Google Scholar] [CrossRef] [PubMed]
  32. Beisswenger, P.J.; Ruggiero-Lopez, D. Metformin inhibition of glycation processes. Diabetes Metab. 2003, 29, 6S95–6S103. [Google Scholar] [CrossRef]
  33. Rahbar, S.; Natarajan, R.; Yerneni, K.; Scott, S.; Gonzales, N.; Nadler, J.L. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin. Chim. Acta 2000, 301, 65–77. [Google Scholar] [CrossRef]
  34. Ruggiero-Lopez, D.; Lecomte, M.; Moinet, G.; Patereau, G.; Lagarde, M.; Wiernsperger, N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem. Pharmacol. 1999, 58, 1765–1773. [Google Scholar] [CrossRef]
  35. Hess, C.; Unger, M.; Madea, B.; Stratmann, B.; Tschoepe, D. Range of therapeutic metformin concentrations in clinical blood samples and comparison to a forensic case with death due to lactic acidosis. Forensic Sci. Int. 2018, 286, 106–112. [Google Scholar] [CrossRef]
  36. Kuan, I.H.S.; Wilson, L.C.; Leishman, J.C.; Cosgrove, S.; Walker, R.J.; Putt, T.L.; Schollum, J.B.W.; Wright, D.F.B. Metformin doses to ensure efficacy and safety in patients with reduced kidney function. PLoS ONE 2021, 16, e0246247. [Google Scholar] [CrossRef]
  37. Hauck, A.K.; Huang, Y.; Hertzel, A.V.; Bernlohr, D.A. Adipose oxidative stress and protein carbonylation. J. Biol. Chem. 2019, 294, 1083–1088. [Google Scholar] [CrossRef] [Green Version]
  38. Ou, J.; Huang, J.; Wang, M.; Ou, S. Effect of rosmarinic acid and carnosic acid on AGEs formation in vitro. Food Chem. 2017, 221, 1057–1061. [Google Scholar] [CrossRef]
  39. Ben Khedher, M.R.; Hafsa, J.; Haddad, M.; Hammami, M. Inhibition of Protein Glycation by Combined Antioxidant and Antiglycation Constituents from a Phenolic Fraction of Sage (Salvia officinalis L.). Plant Foods Hum. 2020, 75, 505–511. [Google Scholar] [CrossRef]
  40. Patil, K.K.; Meshram, R.J.; Dhole, N.A.; Gacche, R.N. Role of dietary flavonoids in amelioration of sugar induced cataractogenesis. Arch. Biochem. Biophys. 2016, 593, 1–11. [Google Scholar] [CrossRef]
  41. Iacobini, C.; Vitale, M.; Pesce, C.; Pugliese, G.; Menini, S. Diabetic complications and oxidative stress: A 20-year voyage back in time and back to the future. Antioxidants 2021, 10, 727. [Google Scholar] [CrossRef] [PubMed]
  42. Aruoma, O.I. Methodological considerations for characterizing potential antioxidant actions of bioactive components in plant foods. Mutat. Res. Fundam. Mol. Mech. Mutagen. 2003, 523–524, 9–20. [Google Scholar] [CrossRef]
  43. Prior, R.L.; Wu, X.; Schaich, K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J. Agric. Food Chem. 2005, 53, 4290–4302. [Google Scholar] [CrossRef]
  44. Chen, Z.; Bertin, R.; Froldi, G. EC50 estimation of antioxidant activity in DPPH• assay using several statistical programs. Food Chem. 2013, 138, 414–420. [Google Scholar] [CrossRef] [PubMed]
  45. Tabart, J.; Kevers, C.; Pincemail, J.; Defraigne, J.-O.; Dommes, J. Comparative antioxidant capacities of phenolic compounds measured by various tests. Food Chem. 2009, 113, 1226–1233. [Google Scholar] [CrossRef]
  46. Anwar, S.; Khan, S.; Almatroudi, A.; Khan, A.A.; Alsahli, M.A.; Almatroodi, S.A.; Rahmani, A.H. A review on mechanism of inhibition of advanced glycation end products formation by plant derived polyphenolic compounds. Mol. Biol. Rep. 2021, 48, 787–805. [Google Scholar] [CrossRef] [PubMed]
  47. Zhang, X.; Li, G.; Wu, D.; Yu, Y.; Hu, N.; Wang, H.; Li, X.; Wu, Y. Emerging strategies for the activity assay and inhibitor screening of alpha-glucosidase. Food Funct. 2020, 11, 66–82. [Google Scholar] [CrossRef]
  48. Djeujo, F.M.; Francesconi, V.; Gonella, M.; Ragazzi, E.; Tonelli, M.; Froldi, G. Anti-alpha-glucosidase and antiglycation Activities of alpha-Mangostin and new xanthenone derivatives: Kinetics and mechanistic insights through in vitro studies. Molecules 2022, 27, 547. [Google Scholar] [CrossRef] [PubMed]
  49. Zhang, B.W.; Li, X.; Sun, W.L.; Xing, Y.; Xiu, Z.L.; Zhuang, C.L.; Dong, Y.S. Dietary Flavonoids and Acarbose Synergistically Inhibit α-Glucosidase and Lower Postprandial Blood Glucose. J. Agric. Food Chem. 2017, 65, 8319–8330. [Google Scholar] [CrossRef]
  50. Yan, J.; Zhang, G.; Pan, J.; Wang, Y. α-Glucosidase inhibition by luteolin: Kinetics, interaction and molecular docking. Int. J. Biol. Macromol. 2014, 64, 213–223. [Google Scholar] [CrossRef]
  51. Zeng, L.; Zhang, G.; Liao, Y.; Gong, D. Inhibitory mechanism of morin on α-glucosidase and its anti-glycation properties. Food Funct. 2016, 7, 3953–3963. [Google Scholar] [CrossRef]
  52. Djeujo, F.M.; Ragazzi, E.; Urettini, M.; Sauro, B.; Cichero, E.; Tonelli, M.; Froldi, G. Magnolol and Luteolin Inhibition of α-Glucosidase Activity: Kinetics and Type of Interaction Detected by In Vitro and In Silico Studies. Pharmaceuticals 2022, 15, 205. [Google Scholar] [CrossRef]
  53. Gao, H.; Nishioha, T.; Kawabata, J.; Kasai, T. Structure-activity relationships for alpha-glucosidase inhibition of baicalein, 5,6,7- trihydroxyflavone: The effect of A-ring substitution. Biosci. Biotechnol. Biochem. 2004, 68, 369–375. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Proença, C.; Freitas, M.; Ribeiro, D.; Oliveira, E.F.T.; Sousa, J.L.C.; Tomé, S.M.; Ramos, M.J.; Silva, A.M.S.; Fernandes, P.A.; Fernandes, E. α-Glucosidase inhibition by flavonoids: An in vitro and in silico structure–activity relationship study. J. Enzym. Inhib. Med. Chem. 2017, 32, 1216–1228. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Fedi, A.; Vitale, C.; Ponschin, G.; Ayehunie, S.; Fato, M.; Scaglione, S. In vitro models replicating the human intestinal epithelium for absorption and metabolism studies: A systematic review. J. Control. Release 2021, 335, 247–268. [Google Scholar] [CrossRef]
  56. Zhang, L.; Lin, G.; Zuo, Z. Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal first-pass metabolism of flavonoid baicalein. Pharm. Res. 2007, 24, 81–89. [Google Scholar] [CrossRef] [PubMed]
  57. Zhang, R.; Cui, Y.; Wang, Y.; Tian, X.; Zheng, L.; Cong, H.J.; Wu, B.; Huo, X.; Wang, C.; Zhang, B.J.; et al. Catechol-O-Methyltransferase and UDP-Glucuronosyltransferases in the Metabolism of Baicalein in Different Species. Eur. J. Drug Metab. Pharmacokinet. 2017, 42, 981–992. [Google Scholar] [CrossRef]
  58. Lu, Q.-Y.; Zhang, L.; Moro, A.; Chen, M.C.; Harris, D.M.; Eibl, G.; Go, V.-L.W. Detection of Baicalin Metabolites Baicalein and Oroxylin-A in Mouse Pancreas and Pancreatic Xenografts. Pancreas 2012, 41, 571–576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Sowndhararajan, K.; Deepa, P.; Kim, M.; Park, S.J.; Kim, S. Baicalein as a potent neuroprotective agent: A review. Biomed. Pharmacother. 2017, 95, 1021–1032. [Google Scholar] [CrossRef] [PubMed]
  60. Zmatliková, Z.; Sedláková, P.; Lacinová, K.; Eckhardt, A.; Pataridis, S.; Mikšík, I. Non-enzymatic posttranslational modifications of bovine serum albumin by oxo-compounds investigated by high-performance liquid chromatography-mass spectrometry and capillary zone electrophoresis-mass spectrometry. J. Chromatogr. A 2010, 1217, 8009–8015. [Google Scholar] [CrossRef]
  61. Yamagishi, S.I.; Nakamura, K.; Matsui, T.; Ueda, S.; Noda, Y.; Imaizumi, T. Inhibitors of advanced glycation end products (AGEs): Potential utility for the treatment of cardiovascular disease. Cardiovasc. Ther. 2008, 26, 50–58. [Google Scholar] [CrossRef]
  62. Rahbar, S.; Yernini, K.K.; Scott, S.; Gonzales, N.; Lalezari, I. Novel inhibitors of advanced glycation endproducts. Biochem. Biophys. Res. Commun. 1999, 262, 651–656. [Google Scholar] [CrossRef]
  63. Levine, R.L.; Garland, D.; Oliver, C.N.; Amici, A.; Climent, I.; Lenz, A.-G.; Ahn, B.-W.; Shaltiel, S.; Stadtman, E.R. Determination of carbonyl content in oxidatively modified proteins. In Oxygen Radicals in Biological Systems Part B: Oxygen Radicals and Antioxidants; Packer, L., Glazer A., N., Eds.; Academic Press: Cambridge, MA, USA, 1990; Volume 186, pp. 464–478. ISBN 00766879. [Google Scholar] [CrossRef]
  64. Georgiou, C.D.; Zisimopoulos, D.; Argyropoulou, V.; Kalaitzopoulou, E.; Salachas, G.; Grune, T. Protein and cell wall polysaccharide carbonyl determination by a neutral pH 2,4-dinitrophenylhydrazine-based photometric assay. Redox Biol. 2018, 17, 128–142. [Google Scholar] [CrossRef] [PubMed]
  65. Smith, P.K.; Krohn, R.I.; Hermanson, G.T.; Mallia, A.K.; Gartner, F.H.; Provenzano, M.D.; Fujimoto, E.K.; Goeke, N.M.; Olson, B.J.; Klenk, D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150, 76–85. [Google Scholar] [CrossRef]
  66. Brand-Williams, W.; Cuvelier, M.E.; Berset, C. Use of a free radical method to evaluate antioxidant activity. LWT Food Sci. Technol. 1995, 28, 25–30. [Google Scholar] [CrossRef]
  67. Ou, B.; Hampsch-Woodill, M.; Prior, R.L. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. J. Agric. Food Chem. 2001, 49, 4619–4626. [Google Scholar] [CrossRef] [PubMed]
  68. Froldi, G.; Baronchelli, F.; Marin, E.; Grison, M. Antiglycation Activity and HT—29 Cellular Uptake of Aloe—Emodin, Aloin, and Aloe arborescens Leaf Extracts. Molecules 2019, 24, 2128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  69. Zhao, Y.; Sun, Y.N.; Lee, M.J.; Kim, Y.H.; Lee, W.; Kim, K.H.; Kim, K.T.; Kang, J.S. Identification and discrimination of three common Aloe species by high performance liquid chromatography–tandem mass spectrometry coupled with multivariate analysis. J. Chromatogr. B 2016, 1031, 163–171. [Google Scholar] [CrossRef]
  70. Lowry, O.; Rosebrough, N.; Farr, A.; Randal, R. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265–275. [Google Scholar] [CrossRef]
Pharmaceutics 14 02141 g001 550
Figure 1. Chemical structures of baicalein, baicalin, and metformin.
Figure 1. Chemical structures of baicalein, baicalin, and metformin.
Pharmaceutics 14 02141 g001
Pharmaceutics 14 02141 g002 550
Figure 2. (A) Time course of AGE fluorescence during incubation of 50 mg/mL BSA with 0.1 M ribose, 0.003 M glyoxal and 0.8 M glucose. (B) Maximal AGE formation after 5 (ribose) and 7 days of incubation with the selected glycation agent. Data are the mean ± SEM of 3–6 experiments. * p < 0.05 and **** p < 0.0001 versus BSA (control). Turkey’s analysis test shows significant differences between BSA+glucose versus BSA+glyoxal or BSA+ribose (p < 0.0001), or BSA+glyoxal versus BSA+Ribose (p < 0.01).
Figure 2. (A) Time course of AGE fluorescence during incubation of 50 mg/mL BSA with 0.1 M ribose, 0.003 M glyoxal and 0.8 M glucose. (B) Maximal AGE formation after 5 (ribose) and 7 days of incubation with the selected glycation agent. Data are the mean ± SEM of 3–6 experiments. * p < 0.05 and **** p < 0.0001 versus BSA (control). Turkey’s analysis test shows significant differences between BSA+glucose versus BSA+glyoxal or BSA+ribose (p < 0.0001), or BSA+glyoxal versus BSA+Ribose (p < 0.01).
Pharmaceutics 14 02141 g002
Pharmaceutics 14 02141 g003 550
Figure 3. Baicalein (green bars), baicalin (yellow bars), and metformin (pink bars) inhibition of AGE formation after 7(A,B) or 5 (C) days of incubation of 50 mg/mL BSA with 0.8 M glucose (A), 0.003 M glyoxal (B), and 0.1 M ribose (C). Aminoguanidine (2.5 mM, AG) was the positive control. Data are the mean ± SEM of 3–6 experiments. * p < 0.05, *** p < 0.001, *** p < 0.001, **** p < 0.0001 versus BSA glycation (BSA + glycation agent).
Figure 3. Baicalein (green bars), baicalin (yellow bars), and metformin (pink bars) inhibition of AGE formation after 7(A,B) or 5 (C) days of incubation of 50 mg/mL BSA with 0.8 M glucose (A), 0.003 M glyoxal (B), and 0.1 M ribose (C). Aminoguanidine (2.5 mM, AG) was the positive control. Data are the mean ± SEM of 3–6 experiments. * p < 0.05, *** p < 0.001, *** p < 0.001, **** p < 0.0001 versus BSA glycation (BSA + glycation agent).
Pharmaceutics 14 02141 g003
Pharmaceutics 14 02141 g004 550
Figure 4. Effects of baicalein (green bars), baicalin (yellow bars), and metformin (pink bars) on GK cross–linking formation after 2 days of incubation of 26.7 mg/mL GK peptide (0.1 M) with 40 mg/mL ribose (0.27 M) reported as fluorescence (A) and percentage of control fluorescence (B). Aminoguanidine (2.5 mM, AG) was the positive control. Data are the mean ± SEM of 3–6 experiments. * p < 0.05, ** p < 0.01, and **** p < 0.0001 versus GK cross–linking (GK + Ribose).
Figure 4. Effects of baicalein (green bars), baicalin (yellow bars), and metformin (pink bars) on GK cross–linking formation after 2 days of incubation of 26.7 mg/mL GK peptide (0.1 M) with 40 mg/mL ribose (0.27 M) reported as fluorescence (A) and percentage of control fluorescence (B). Aminoguanidine (2.5 mM, AG) was the positive control. Data are the mean ± SEM of 3–6 experiments. * p < 0.05, ** p < 0.01, and **** p < 0.0001 versus GK cross–linking (GK + Ribose).
Pharmaceutics 14 02141 g004
Pharmaceutics 14 02141 g005 550
Figure 5. Effects of baicalein (green bars) and baicalin (yellow bars) on carbonyl content, detected with 50 mg/mL BSA and 0.1 M ribose, reported as carbonyl content and expressed in nmol/mg protein. Aminoguanidine (2.5 mM, AG) was the positive control. Data are the mean ± SEM of 3–6 experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 versus maximal carbonyl content (BSA + Ribose).
Figure 5. Effects of baicalein (green bars) and baicalin (yellow bars) on carbonyl content, detected with 50 mg/mL BSA and 0.1 M ribose, reported as carbonyl content and expressed in nmol/mg protein. Aminoguanidine (2.5 mM, AG) was the positive control. Data are the mean ± SEM of 3–6 experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 versus maximal carbonyl content (BSA + Ribose).
Pharmaceutics 14 02141 g005
Pharmaceutics 14 02141 g006 550
Figure 6. Antiradical activity of baicalein, baicalin, and metformin detected with DPPH• (A) and ORAC (B) assays. Positive controls: ascorbic acid and N–acetylcysteine (NAC). Data are the mean ± SEM of 3–6 experiments. **** p < 0.0001 versus positive controls. ORAC values are expressed as TEAC (trolox equivalent antioxidant capacity, µmol TE/µmol compound).
Figure 6. Antiradical activity of baicalein, baicalin, and metformin detected with DPPH• (A) and ORAC (B) assays. Positive controls: ascorbic acid and N–acetylcysteine (NAC). Data are the mean ± SEM of 3–6 experiments. **** p < 0.0001 versus positive controls. ORAC values are expressed as TEAC (trolox equivalent antioxidant capacity, µmol TE/µmol compound).
Pharmaceutics 14 02141 g006
Pharmaceutics 14 02141 g007 550
Figure 7. (A) An example of kinetic curves of 0.05 µM α–glucosidase, using 2 mM pNPG as substrate, in the presence of increasing concentrations of baicalein. (B) Inhibition of baicalein was studied using four different concentrations of α–glucosidase: 0.035, 0.05, 0.07 and 0.1 µM. (C) Plot of enzyme activity (v) versus α–glucosidase enzyme concentration. Data are reported as mean ± SEM of 3–6 experiments.
Figure 7. (A) An example of kinetic curves of 0.05 µM α–glucosidase, using 2 mM pNPG as substrate, in the presence of increasing concentrations of baicalein. (B) Inhibition of baicalein was studied using four different concentrations of α–glucosidase: 0.035, 0.05, 0.07 and 0.1 µM. (C) Plot of enzyme activity (v) versus α–glucosidase enzyme concentration. Data are reported as mean ± SEM of 3–6 experiments.
Pharmaceutics 14 02141 g007
Pharmaceutics 14 02141 g008 550
Figure 8. Michaelis–Menten (A) and Lineaweaver–Burk (B) graphs of α–glucosidase activity with different substrate concentrations (0.5–2.0 mM pNPG) in the presence of baicalein (1–100 µM). Data are obtained from 4–5 experiments.
Figure 8. Michaelis–Menten (A) and Lineaweaver–Burk (B) graphs of α–glucosidase activity with different substrate concentrations (0.5–2.0 mM pNPG) in the presence of baicalein (1–100 µM). Data are obtained from 4–5 experiments.
Pharmaceutics 14 02141 g008
Pharmaceutics 14 02141 g009 550
Figure 9. HPLC chromatographic analysis of compounds detected in HT–29 cells after 3 h of incubation of 5 µM baicalein. Chromatograms of the intracellular, extracellular, and standard contents are reported. The panels on the right show the UV spectra of the peaks revealed during the analysis. Peak 1 has been identified as baicalein-7-glucuronide (baicalin), while peaks 2 and 3 are unknown metabolites. Standard baicalein peak 4, Rt 6.53 min; baicalin standard, peak 1, Rt 3.83 min.
Figure 9. HPLC chromatographic analysis of compounds detected in HT–29 cells after 3 h of incubation of 5 µM baicalein. Chromatograms of the intracellular, extracellular, and standard contents are reported. The panels on the right show the UV spectra of the peaks revealed during the analysis. Peak 1 has been identified as baicalein-7-glucuronide (baicalin), while peaks 2 and 3 are unknown metabolites. Standard baicalein peak 4, Rt 6.53 min; baicalin standard, peak 1, Rt 3.83 min.
Pharmaceutics 14 02141 g009
Pharmaceutics 14 02141 g010 550
Figure 10. Intracellular baicalin content measured in HT–29 cells after 3 h of incubation with baicalein (1–50 µM, (A)), and baicalein and baicalin at 5 µM (B). Each value represents the mean ± SEM of at least 3 experiments. ** p < 0.01, *** p < 0.001 and **** p < 0.0001 versus intracellular baicalin content detected using baicalein 1 µM (A) or baicalein 5 µM (B).
Figure 10. Intracellular baicalin content measured in HT–29 cells after 3 h of incubation with baicalein (1–50 µM, (A)), and baicalein and baicalin at 5 µM (B). Each value represents the mean ± SEM of at least 3 experiments. ** p < 0.01, *** p < 0.001 and **** p < 0.0001 versus intracellular baicalin content detected using baicalein 1 µM (A) or baicalein 5 µM (B).
Pharmaceutics 14 02141 g010
Pharmaceutics 14 02141 g011 550
Figure 11. Flowchart of the experimental protocol used to assess the cell uptake of baicalein and baicalin.
Figure 11. Flowchart of the experimental protocol used to assess the cell uptake of baicalein and baicalin.
Pharmaceutics 14 02141 g011
Table
Table 1. Inhibitory potency of baicalein with four different α–glucosidase concentrations.
Table 1. Inhibitory potency of baicalein with four different α–glucosidase concentrations.
Baicalein (IC50)
α-Glucosidase10−5 MpD2
0.0351.814.74 ± 0.02 a
0.052.414.62 ± 0.04 a
0.075.164.29 ± 0.07 a
0.1055.493.26 ± 0.26 b
IC50: half maximal inhibitory concentration of enzyme activity. Data are obtained using the non-linear regression of the normalized response of 4–5 experiments. pD2: −Log IC50. a,b Different superscript letters indicate significant difference (p < 0.0001).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Froldi, G.; Djeujo, F.M.; Bulf, N.; Caparelli, E.; Ragazzi, E. Comparative Evaluation of the Antiglycation and Anti-α-Glucosidase Activities of Baicalein, Baicalin (Baicalein 7-O-Glucuronide) and the Antidiabetic Drug Metformin. Pharmaceutics 2022, 14, 2141. https://doi.org/10.3390/pharmaceutics14102141

AMA Style

Froldi G, Djeujo FM, Bulf N, Caparelli E, Ragazzi E. Comparative Evaluation of the Antiglycation and Anti-α-Glucosidase Activities of Baicalein, Baicalin (Baicalein 7-O-Glucuronide) and the Antidiabetic Drug Metformin. Pharmaceutics. 2022; 14(10):2141. https://doi.org/10.3390/pharmaceutics14102141

Chicago/Turabian Style

Froldi, Guglielmina, Francine Medjiofack Djeujo, Nadia Bulf, Emma Caparelli, and Eugenio Ragazzi. 2022. "Comparative Evaluation of the Antiglycation and Anti-α-Glucosidase Activities of Baicalein, Baicalin (Baicalein 7-O-Glucuronide) and the Antidiabetic Drug Metformin" Pharmaceutics 14, no. 10: 2141. https://doi.org/10.3390/pharmaceutics14102141

APA Style

Froldi, G., Djeujo, F. M., Bulf, N., Caparelli, E., & Ragazzi, E. (2022). Comparative Evaluation of the Antiglycation and Anti-α-Glucosidase Activities of Baicalein, Baicalin (Baicalein 7-O-Glucuronide) and the Antidiabetic Drug Metformin. Pharmaceutics, 14(10), 2141. https://doi.org/10.3390/pharmaceutics14102141

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop